Once present in the TME, these neutrophils act as “therapeutic sinks” that sequester anti-PD-L1 antibodies; mathematical modeling confirms that therapeutic responses are more sensitive to PD-L1 levels on immune cells than on tumor cells [44,45,54]. This evidence concerns the gene CD274 and neoplasm.